

# UCSF

## UC San Francisco Previously Published Works

### Title

Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic

### Permalink

<https://escholarship.org/uc/item/7fw5603w>

### Journal

PLOS Biology, 16(10)

### ISSN

1544-9173

### Authors

Boehme, Jason  
Le Moan, Natacha  
Kameny, Rebecca J  
[et al.](#)

### Publication Date

2018

### DOI

10.1371/journal.pbio.2005924

Peer reviewed

SHORT REPORTS


# Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic

Jason Boehme<sup>1‡</sup>, Natacha Le Moan<sup>2‡</sup>, Rebecca J. Kameny<sup>1</sup>, Alexandra Loucks<sup>2</sup>, Michael J. Johengen<sup>1</sup>, Amy L. Lesneski<sup>1</sup>, Wenhui Gong<sup>1</sup>, Brian D. Goudy<sup>1</sup>, Tina Davis<sup>2</sup>, Kevin Tanaka<sup>2</sup>, Andrew Davis<sup>2</sup>, Youping He<sup>1</sup>, Janel Long-Boyle<sup>3,4</sup>, Vijay Ivaturi<sup>4,5</sup>, Jogarao V. S. Gobburu<sup>4,5</sup>, Jonathan A. Winger<sup>2</sup>, Stephen P. Cary<sup>2</sup>, Sanjeev A. Datar<sup>1</sup>, Jeffrey R. Fineman<sup>1,4</sup>, Ana Krtolica<sup>2\*</sup>, Emin Maltepe<sup>1,4\*</sup>

**1** Department of Pediatrics, University of California, San Francisco, San Francisco, California, United States of America, **2** Omnix, Inc., San Carlos, California, United States of America, **3** Department of Clinical Pharmacology, University of California, San Francisco, San Francisco, California, United States of America, **4** Initiative for Pediatric Drug and Device Development (iPD3), San Francisco, California, United States of America, **5** School of Pharmacy, University of Maryland, Baltimore, United States of America

‡ These authors share first authorship on this work.

\* [akrtolica@omnixinc.com](mailto:akrtolica@omnixinc.com) (AK); [emin.maltepe@ucsf.edu](mailto:emin.maltepe@ucsf.edu) (EM)



**OPEN ACCESS**

**Citation:** Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, et al. (2018) Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. *PLoS Biol* 16(10): e2005924. <https://doi.org/10.1371/journal.pbio.2005924>

**Academic Editor:** Cecilia Lo, University of Pittsburgh, United States of America

**Received:** March 16, 2018

**Accepted:** September 13, 2018

**Published:** October 18, 2018

**Copyright:** © 2018 Boehme et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** NIH <https://www.nichd.nih.gov/> (grant number HD072455). Received by EM. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NIH <https://www.nhlbi.nih.gov/> (grant number HL133034). Received by SAD and EM. The funder had no role in study design, data collection

## Abstract

The heart exhibits the highest basal oxygen (O<sub>2</sub>) consumption per tissue mass of any organ in the body and is uniquely dependent on aerobic metabolism to sustain contractile function. During acute hypoxic states, the body responds with a compensatory increase in cardiac output that further increases myocardial O<sub>2</sub> demand, predisposing the heart to ischemic stress and myocardial dysfunction. Here, we test the utility of a novel engineered protein derived from the heme-based nitric oxide (NO)/oxygen (H-NOX) family of bacterial proteins as an O<sub>2</sub> delivery biotherapeutic (Omniox-cardiovascular [OMX-CV]) for the hypoxic myocardium. Because of their unique binding characteristics, H-NOX-based variants effectively deliver O<sub>2</sub> to hypoxic tissues, but not those at physiologic O<sub>2</sub> tension. Additionally, H-NOX-based variants exhibit tunable binding that is specific for O<sub>2</sub> with subphysiologic reactivity towards NO, circumventing a significant toxicity exhibited by hemoglobin (Hb)-based O<sub>2</sub> carriers (HBOCs). Juvenile lambs were sedated, mechanically ventilated, and instrumented to measure cardiovascular parameters. Biventricular admittance catheters were inserted to perform pressure-volume (PV) analyses. Systemic hypoxia was induced by ventilation with 10% O<sub>2</sub>. Following 15 minutes of hypoxia, the lambs were treated with OMX-CV (200 mg/kg IV) or vehicle. Acute hypoxia induced significant increases in heart rate (HR), pulmonary blood flow (PBF), and pulmonary vascular resistance (PVR) ( $p < 0.05$ ). At 1 hour, vehicle-treated lambs exhibited severe hypoxia and a significant decrease in biventricular contractile function. However, in OMX-CV-treated animals, myocardial oxygenation was improved without negatively impacting systemic or PVR, and both right ventricle (RV) and left ventricle (LV) contractile function were maintained at pre-hypoxic baseline levels. These data suggest that OMX-CV is a promising

and analysis, decision to publish, or preparation of the manuscript. NIH <https://www.nichd.nih.gov/> (grant number HD094414). Received by AK, JRF, and EM. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NIH <https://www.nhlbi.nih.gov/> (grant number HL061284). Received by JRF. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. PTBi-CA (grant number 7028203). Received by EM and JRF. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** EM and JRF are consultants to Omnix, Inc.

**Abbreviations:** bpm, beats per minute; ESPVR, end systolic pressure-volume relationship; Hb, hemoglobin; HBOC, Hb-based O<sub>2</sub> carrier; H-NOX, heme-based nitric oxide/oxygen; HR, heart rate; IF, immunofluorescent; iLPA, indexed left pulmonary artery; iLPAQ, indexed left pulmonary artery flow; iLPAVR, indexed left pulmonary artery vascular resistance; iLPVR, indexed left pulmonary vascular resistance; IVC, inferior vena cava; **K<sub>D</sub>**, **dissociation constant**; LPA, left pulmonary artery; LV, left ventricle; methHb, methemoglobin; **mmHg**, **millimeters mercury**; MPA, main pulmonary artery; NO, nitric oxide; O<sub>2</sub>, oxygen; OMX-CV, Omnix-cardiovascular; PA, pulmonary artery; PaO<sub>2</sub>, arterial oxygen tension; PAP, pulmonary artery pressure; PBF, pulmonary blood flow; PEG, polyethylene glycol; PO<sub>2</sub>, partial pressure of oxygen; post-bt, immediately following treatment administration; pre-bt, immediately prior to treatment administration; PV, pressure-volume; PVR, pulmonary vascular resistance; RBC, red blood cell; ROS, reactive oxygen species; RV, right ventricle; SVR, systemic vascular resistance; Tt, *Thermoanaerobacter tengcongensis*.

and safe O<sub>2</sub> delivery biotherapeutic for the preservation of myocardial contractility in the setting of acute hypoxia.

## Author summary


While hemoglobin is the primary oxygen delivery molecule used to maintain tissue oxygenation in metazoans, many organisms have other heme-containing proteins that can bind oxygen and other diatomic gases. Here, we tested whether a member of the H-NOX family of heme-containing proteins found in the thermostable bacterium *Thermoanaerobacter tengcongensis* can be engineered to deliver oxygen to severely hypoxic tissues in large mammals. This class of molecules has the advantage of high oxygen affinity and minimal nitric oxide reactivity. We demonstrate that these molecules can effectively deliver oxygen to a lamb heart with induced severe hypoxia, without overexposing the animal to oxygen or triggering systemic vascular reactivity. These molecules thus represent a novel class of oxygen delivery biotherapeutics to specifically target hypoxic tissue beds without the toxicity concerns of hemoglobin-based oxygen carriers. As tissue hypoxia is a central feature of many disease processes, this therapeutic approach may have broad clinical applicability.

## Introduction

Inadequate oxygen (O<sub>2</sub>) delivery relative to metabolic demand leads to progressive bioenergetic collapse and cellular dysfunction. When systemic, this defines the clinical entity of shock, a major cause of morbidity and mortality in both adults and children [1,2,3,4]. Rather than a specific disease state, shock is a shared pathologic end point arising from disorders such as respiratory failure, hemorrhage, or sepsis that ultimately impair cardiovascular function. For this reason, maintaining a balance between myocardial O<sub>2</sub> supply and demand underlies a central therapeutic framework of critical care medicine.

Of all organs, the heart is metabolically unique both in regard to its energetic demands as well as its O<sub>2</sub> utilization and extraction characteristics. Given its primary physiologic function as a continuous generator of mechanical force, the heart requires an extraordinary supply of biochemical energy and exhibits a far greater rate of ATP turnover than any other organ [5]. Furthermore, the heart is exquisitely dependent on aerobic metabolism to meet these high bioenergetic needs, without the ability to derive any meaningful contribution from anaerobic pathways such as glycolysis [6]. This is reflected in the large myocardial volume devoted to mitochondria and the heart's status as the highest O<sub>2</sub> consumer per gram tissue mass of any organ [5,6]. Importantly, its high O<sub>2</sub> extraction ratio results in lower venous O<sub>2</sub> contents than other tissues, with a significant fraction of cardiomyocytes being exposed to physiologically hypoxic environments at baseline [7,8]. When myocardial O<sub>2</sub> supply becomes limited in the face of increased demand, dramatic increases in coronary blood flow as well as cardiomyocyte O<sub>2</sub> extraction attempt to compensate [7,8,9]. When inadequate, biochemical signs of a switch to anaerobic metabolism are accompanied by an immediate impairment of contractile function [10]. O<sub>2</sub> consumption is thus vital to provide the biochemical energy required to maintain cardiac mechanical function.

In this study, we describe, for the first time, the use of a novel O<sub>2</sub> delivery biotherapeutic to alleviate hypoxia-induced tissue dysfunction in the heart. Derived from the heme-based nitric



**Fig 1. Illustration of OMX-CV H-NOX protein and its oxygen-binding characteristics.** (A) Ribbon diagrams depicting an H-NOX protein monomer, H-NOX protein trimer, and PEGylated H-NOX protein trimer. The heme cofactor and the bound oxygen are depicted in yellow and red. Models were made using a *Tt* H-NOX structure (PDB ID 1U4H) and PyMOL [17]. (B) Illustration depicting the relative oxygen affinities of hemoglobin, *Tt* H-NOX, and OMX-CV overlaid on an oxygen gradient from normoxia to hypoxia. The oxygen affinity of hemoglobin facilitates release of oxygen in peripheral tissues ( $\text{PO}_2$  of about 40 mmHg), while the oxygen affinity of OMX-CV facilitates release of oxygen into hypoxic tissues ( $\text{PO}_2$  of about 10 mmHg). **H-NOX**, heme-based nitric oxide/oxygen;  **$K_D$** , dissociation constant; **mmHg**, millimeters mercury; **OMX-CV**, Omniox-cardiovascular; **PEG**, polyethylene glycol;  **$\text{PO}_2$** , partial pressure of oxygen; ***Tt***, *Thermoanaerobacter tengcongensis*.

<https://doi.org/10.1371/journal.pbio.2005924.g001>

oxide (NO)/oxygen (H-NOX) sensing proteins found in the thermostable bacterium *Thermoanaerobacter tengcongensis* (*Tt*) [11], the protein component of Omniox-cardiovascular (OMX-CV) is engineered via trimerization and polyethylene glycol (PEG)-ylation (as illustrated in Fig 1A) to increase circulation half-life, and alterations to the heme-binding pocket to fine-tune both selectivity and avidity of interaction with the diatomic gases NO and molecular  $\text{O}_2$  [12,13]. Unlike hemoglobin (Hb)-based  $\text{O}_2$  delivery biotherapeutics that scavenged NO and therefore triggered significant vascular sequelae, including hypertension, renal dysfunction, and

increased risk of myocardial infarction and death [14,15,16], the protein component of OMX-CV is uniquely tuned to bind molecular O<sub>2</sub> in a way that reduces NO reactivity 50-fold compared with Hb [13], alleviating the potential risk of vasoconstriction.

Additionally, relative to Hb, the protein component of OMX-CV binds to O<sub>2</sub> with a very high affinity, exhibiting a dissociation constant ( $K_D$ ) of about 2.4  $\mu$ M [13]. Fig 1B shows a schematic comparing the O<sub>2</sub> affinities of wild-type Tt H-NOX and OMX-CV with that of Hb, and illustrates how OMX-CV can effectively deliver O<sub>2</sub> only to tissues that are significantly hypoxic while bypassing those at physiologic O<sub>2</sub> tensions. Following O<sub>2</sub> delivery within the hypoxic capillary environment, the unbound OMX-CV molecules enter the systemic venous and pulmonary vascular beds. In this manner, OMX-CV circulates and can be predicted to sustain an ongoing, targeted O<sub>2</sub> delivery to the most hypoxic organs and tissues without unnecessary and potentially harmful [18] oxygenation of tissues at physiologic O<sub>2</sub> tensions.

We hypothesized that in the setting of severe myocardial hypoxia, OMX-CV administration would increase O<sub>2</sub> delivery to the heart and improve cardiac mechanical function. In order to test this hypothesis, we utilized a juvenile lamb model of severe acute alveolar hypoxia. The lamb is a robust large animal model that has been extensively utilized because of its close approximation of human cardiovascular function [19]. Here, we present data regarding the safety and efficacy of OMX-CV administration in the setting of systemic hypoxia supporting the use of OMX-CV as a promising novel O<sub>2</sub> delivery biotherapeutic.


## Results

### Acute alveolar hypoxia induces a dramatic physiologic response

Previous studies have described the acute cardiovascular response to progressive alveolar hypoxia in large animal models [20,21]. Here, we established a model of acute alveolar hypoxia in juvenile lambs triggered via inhalation of a gas mixture containing 10% O<sub>2</sub> (Fig 2A). Physiologic data were compared at pre-hypoxic baseline and at 15 minutes of hypoxia (prior to experimental intervention) for all animals included in the analysis ( $n = 13$ ). As expected, we witnessed a precipitous fall in arterial O<sub>2</sub> tension (PaO<sub>2</sub>) with the onset of alveolar hypoxia that was then sustained for the duration of the study (Fig 2B). Fig 2C–2F demonstrate the dramatic changes in physiologic parameters that accompany this severe hypoxemia at the 15-minute time point. The animals all exhibit acute increases in heart rate (HR), systemic blood pressure (systolic and mean), pulmonary blood pressure (systolic, diastolic, and mean), and left and right atrial pressures. As expected [22], there is a significant increase in pulmonary vascular resistance (PVR) attributable to hypoxic pulmonary vasoconstriction. However, there is not a significant alteration in either systemic diastolic blood pressure or systemic vascular resistance (SVR). Additionally, there is an overall increase in cardiac output of approximately 15% (Fig 2G). Although this just fails to reach statistical significance when evaluated at the 15-minute time point ( $p = .063$ ), there is a significant increase in cardiac output amongst all animals (but no between-group difference) when evaluated over the duration of the hypoxic exposure (Fig 3). Table 1 provides additional cardiovascular physiologic parameters comparing OMX-CV and vehicle groups at their respective hypoxic baselines (before drug) and study conclusion (60 minutes).

### OMX-CV administration does not cause systemic or pulmonary vasoconstriction


Taking into consideration the historical challenges related to NO scavenging encountered in the use of hemoglobin-based oxygen carriers (HBOCs), we evaluated the physiologic impact of



**Fig 2. Physiologic responses of the cardiovascular system to acute alveolar hypoxia.** (A) Schematic of experimental protocol. Physiologic measurements were continuously recorded and logged every second for the duration of the study. At each designated time point, physiologic data were averaged over a 60-second period in 5-second intervals. (B) Average measured PaO<sub>2</sub> in mmHg of all animals (*n* = 13) at baseline (Bsl) compared with 15 minutes following institution of hypoxic ventilation. (C) Average heart rate of all animals at Bsl compared with 15 minutes following institution of hypoxic ventilation. (D) Average mean pulmonary arterial pressure (in mmHg) of all animals at Bsl compared with 15 minutes following institution of hypoxic ventilation. (E) Average mean systemic arterial pressure (in mmHg) of all animals at Bsl compared with 15 minutes following institution of hypoxic ventilation. (F) Average indexed PVR of all animals at baseline (Bsl) compared with 15 minutes following institution of hypoxic ventilation. PVR of the left lung was calculated as the difference of mean pulmonary arterial pressure and left atrial pressure divided by the indexed LPA blood flow. (G) Average indexed left pulmonary arterial blood flow of all animals at Bsl compared with 15 minutes following institution of hypoxic ventilation. Flow was indexed to body size by dividing by the animal's weight in kilograms. In all figures, "\*" denotes significance with *p* < 0.05, while "ns" denotes *p* > 0.05. Error bars demonstrate standard error of the mean. Primary data can be found in [S1 Table](#). bpm, beats per minute; Bsl, baseline; iLPAQ, indexed left pulmonary artery flow; iLPVR, indexed left pulmonary vascular resistance; LPA, left pulmonary artery; mmHg, millimeters mercury; OMX-CV, Omnix-cardiovascular; PA, pulmonary artery; PaO<sub>2</sub>, arterial oxygen tension; Veh, vehicle.

<https://doi.org/10.1371/journal.pbio.2005924.g002>





**Fig 3. Cardiac output in control and OMX-CV-treated animals.** Indexed left pulmonary arterial blood flow in vehicle- versus OMX-CV-treated groups over the duration of the experimental protocol. Time 0 represents the physiologic baseline and other time points represent total duration of hypoxic ventilation. Error bars correspond to the standard error of the mean. There is a statistically significant interaction between time and iLPA flow ( $p < 0.05$ ) by two-way ANOVA. There is no significant difference between OMX-CV ( $n = 6$ ) and vehicle ( $n = 7$ ) groups. Primary data can be found in [S1 Table](#). iLPA, indexed left pulmonary artery; OMX-CV, Omnixo-cardiovascular; Veh, vehicle.

<https://doi.org/10.1371/journal.pbio.2005924.g003>

OMX-CV administration on systemic and pulmonary vascular reactivity. Importantly, the total amount of OMX-CV administered relative to circulating Hb is quite low. In an average 10-kg lamb with a serum Hb concentration of 10 g/dL and a circulating blood volume of 70 mL/kg, Hb O<sub>2</sub> carrying capacity is approximately 4.8 mM. For these experiments, we provided approximately 54 mL total of OMX-CV infusion, representing an infused OMX-CV O<sub>2</sub>-binding capacity of approximately 0.1 mM, or 2% that of circulating Hb. As noted in [Table 1](#), this does not result in appreciable differences in circulating PaO<sub>2</sub> values but is readily available for oxygenating severely hypoxic tissues. Given the substantial physiologic changes induced by the hypoxic stimulus, we specifically evaluated effects on SVR and PVR in the setting of systemic hypoxia prior to and immediately following drug or vehicle administration ( $n = 7$  control and  $n = 6$  OMX-CV). As seen in [Fig 4](#), we observed no significant increase in either the indexed PVR ([Fig 4A](#)) or indexed SVR ([Fig 4B](#)) with administration of OMX-CV when compared with vehicle control under hypoxic conditions. Furthermore, there was no difference in the absolute value or percent change between the OMX-CV-treated and vehicle-treated groups. While hypoxia clearly results in a pre-constricted pulmonary vasculature, this occurs through a NO-independent mechanism, and PVR would be expected to remain quite sensitive to abrupt changes in NO signaling [23,24]. Additionally, SVR is also increased during hypoxia, as evidenced by increased mean systemic pressure, and was similarly unaffected by OMX-CV administration ([Fig 4B](#)), affirming a lack of direct vasoreactivity.

**Table 1. A compilation of cardiovascular physiologic parameters measured during hypoxic conditions in lambs receiving vehicle or OMX-CV.** Primary data can be found in [S1 Table](#).

Parameters	Time point	Vehicle	OMX-CV	p-value
		Avg ± SD	Avg ± SD	
Hgb		9.38 ± 1.2	9.32 ± 1.5	0.83
PaO <sub>2</sub>	Hypoxia Bsln	18 ± 2.3	21 ± 4.3	0.28
	Hypoxia 60 min	22.7 ± 1.7	21.7 ± 2.1	0.78
Systolic SAP	Hypoxia Bsln	127.9 ± 24	119.3 ± 28.5	0.65
	Hypoxia 60 min	105.5 ± 23.9	102.43 ± 29.7	0.77
Diastolic SAP	Hypoxia Bsln	64.1 ± 19.7	60.4 ± 18.7	0.98
	Hypoxia 60 min	42.0 ± 10.5	48.9 ± 19.8	0.55
Mean SAP	Hypoxia Bsln	81.9 ± 19.9	81.3 ± 17.3	0.83
	Hypoxia 60 min	61.3 ± 14	67.7 ± 19.1	0.60
HR	Hypoxia Bsln	158.0 ± 19.5	169.6 ± 44.9	0.50
	Hypoxia 60 min	193.4 ± 28.2	184.1 ± 24.3	0.75
Systolic PAP	Hypoxia Bsln	35.3 ± 4.0	38.0 ± 9.4	0.57
	Hypoxia 60 min	36.0 ± 3.3	39.5 ± 8.2	0.38
Diastolic PAP	Hypoxia Bsln	15.4 ± 3.9	13.5 ± 3.8	0.46
	Hypoxia 60 min	16.2 ± 2.3	15.7 ± 3.8	0.92
Mean PAP	Hypoxia Bsln	24.0 ± 3.5	23.7 ± 4.8	0.81
	Hypoxia 60 min	25.0 ± 2.3	25.9 ± 4.7	0.68
LAP	Hypoxia Bsln	3.5 ± 1.9	5.7 ± 1.9	0.07
	Hypoxia 60 min	4.4 ± 1.7	5.7 ± 1.6	0.02
RAP	Hypoxia Bsln	2.8 ± 1.2	4.6 ± 1.5	0.05
	Hypoxia 60 min	4.8 ± 2.5	4.9 ± 1.8	0.94
iLPAQ	Hypoxia Bsln	0.051 ± 0.006	0.056 ± 0.012	0.36
	Hypoxia 60 min	0.052 ± 0.007	0.055 ± 0.011	0.56
iLPAVR	Hypoxia Bsln	414.9 ± 107.1	332.2 ± 70.1	0.12
	Hypoxia 60 min	402.3 ± 62.3	375.3 ± 97.9	0.46


Abbreviations: Avg, average; Bsln, baseline; Hgb, hemoglobin; HR, heart rate; iLPAQ, indexed left pulmonary artery flow; iLPAVR, indexed left pulmonary artery vascular resistance; LAP, left atrial pressure; OMX-CV, Omniox-cardiovascular; PaO<sub>2</sub>, arterial oxygen tension; PAP, pulmonary artery pressure; RAP, right atrial pressure; SAP, systemic arterial pressure.

<https://doi.org/10.1371/journal.pbio.2005924.t001>

### OMX-CV decreases myocardial hypoxia

To directly assess the effect of OMX-CV on myocardial tissue oxygenation, following the final assessment of physiologic parameters, pimonidazole (Hypoxyprobe, 85 mg/kg), a well-established marker of tissue hypoxia [25], was administered intravenously to a subset of animals (*n* = 3 per treatment group). Thirty minutes after administration of pimonidazole, the animals were humanely killed and tissues collected for processing and measurement of pimonidazole adduct levels in the ventricular myocardium. Pimonidazole freely diffuses into cells and is competitively metabolized via oxidative or reductive chemical reactions, depending on the tissue O<sub>2</sub> content. In severely hypoxic environments (below 10 mm Hg), reductive metabolism is favored and in its reduced state, pimonidazole forms covalent adducts with sulfhydryl groups of proteins and glutathione, leading to accumulation of pimonidazole adducts inside the cell [25]. Pimonidazole adducts can be recognized using pimonidazole-targeted primary antibodies and quantified using standard ELISA and immunofluorescent (IF) methods. As seen in [Fig 5A & 5B](#), the OMX-CV-treated animals exhibited a significant reduction in myocardial hypoxia compared with controls, as evidenced by lower levels of bound






**Fig 4. SVR and PVR before and after OMX-CV and vehicle administration.** (A) Indexed PVR in vehicle- ( $n = 7$ ) and OMX-CV-treated ( $n = 6$ ) animals during hypoxic ventilation immediately prior to (pre-txt) and following (post-txt) treatment administration. There are no statistically significant differences between groups or within groups pre- and posttreatment. Error bars represent the standard error of the mean. (B) Indexed SVR in vehicle- and OMX-CV-treated animals pre-txt and post-txt. There are no statistically significant differences between groups or within groups pre- and posttreatment. Error bars represent the standard error of the mean. Primary data can be found in [S1 Table](#). OMX-CV, Omnix-cardiovascular; post-txt, immediately following treatment administration; pre-txt, immediately prior to treatment administration; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance; Veh, vehicle.

<https://doi.org/10.1371/journal.pbio.2005924.g004>

pimonidazole observed via IF microscopy and quantified by ELISA. To verify that the improved myocardial tissue oxygenation in the OMX-CV group was mediated by transcappillary  $O_2$  diffusion, rather than vascular extravasation, IF microscopy was performed with antibodies directed against OMX-CV. As seen in [Fig 5C](#), OMX-CV localized within the capillary vascular spaces throughout the heart and not the extracellular spaces surrounding the cardiomyocytes. Thus, at tested doses, a high-affinity  $O_2$  delivery biotherapeutic can relieve tissue hypoxia in the heart.

### OMX-CV preserves myocardial contractility during systemic hypoxia

To determine whether this improvement in myocardial  $O_2$  delivery translates into a physiologic benefit, we utilized cardiac pressure volume loop analysis to evaluate contractile function of the bilateral ventricles. As noted previously by other groups, evaluation of cardiac function in intact animal studies is often obscured by compensatory physiologic alterations to ventricular loading conditions and sympathetic tone [10,21]. Indeed, we observed in our own data that from the onset of hypoxia, both the OMX-CV and control groups exhibited similar elevations in cardiac output (about 15%) above the normoxic baseline, and that this was sustained throughout our study ([Fig 3](#)). This suggests a full mobilization of compensatory mechanisms that may account for the lack of a significant difference in cardiac output between the OMX-CV and control groups at early time points. Initially advanced by Suga and Sagawa in the 1970s [26], evaluation of two-dimensional ventricular pressure-volume (PV) loops with a focus on the end systolic pressure-volume relationship (ESPVR) is now the widely adopted standard used to assess the load-independent contractile state of the ventricles [27]. This method has previously been used to validate the hypoxic depression of myocardial contractile function in dogs and shown to correlate closely with myocardial  $O_2$  deficiency and the onset of anaerobic metabolism [8,10].




**Fig 5. Myocardial hypoxia in control and OMX-CV-treated animals.** In a subset of vehicle- and OMX-CV-treated animals ( $n = 3$  each), following measurement of physiologic parameters, pimonidazole was administered intravenously and tissues were collected for analysis 30 minutes later. (A) Quantification of pimonidazole adducts in vehicle- and OMX-CV-treated myocardial tissue by pimonidazole ELISA. Values are  $\pm$ SEM,  $*p < 0.05$  by Student  $t$  test. (B) Representative images of vehicle- and OMX-CV-treated myocardium tissue sections immunostained with antibodies targeting pimonidazole adducts. (C) Representative images of OMX-CV-treated myocardial tissue sections immunostained with antibodies targeting the OMX-CV molecule. OMX-CV, Omnix-cardiovascular; pimo, pimonidazole; Veh, vehicle.

<https://doi.org/10.1371/journal.pbio.2005924.g005>

In order to delineate the ESPVR, a family of loops was generated (as seen in Fig 6A & 6B) through transient preload suppression induced by graduated occlusion of the inferior vena cava (IVC). The slope of the tangent connecting the end systolic points of these loops gives the most precise representation of intrinsic contractility of the ventricle. As seen in Fig 6A, which shows a representative set of loops and their ESPVR from the LV of a control animal, the decline in slope from baseline (black) to hypoxia (green) demonstrates a decrease in contractility. In contrast, the LV loops of an OMX-CV-treated animal (Fig 6B) exhibit an increasing slope, indicating an improvement in contractile function. By normalizing the slope of the ESPVR at 60 minutes to the baseline for each animal ( $n = 7$  control and  $n = 6$  OMX-CV), we observed that OMX-CV-treated animals maintained an average contractility up to 2-fold above their own baseline under hypoxic conditions (Fig 6C), while RV (Fig 6C) and LV (Fig 6D) contractility were both reduced in vehicle controls. These data indicate that OMX-CV treatment was able to reverse the effects of myocardial hypoxia and preserve cardiac contractility.

We finally explored the role of sympathetic activation in the cardiovascular response to acute alveolar hypoxia by measuring plasma levels of the sympathetic hormones epinephrine and norepinephrine at baseline and after 60 minutes of hypoxia. Released by the adrenal medulla in response to increased stimulation of the sympathetic nervous system, these hormones exhibit potent cardiovascular effects mediated through binding of alpha- and beta-adrenergic receptors in the heart and vasculature. Similar to what has been described [21], we



**Fig 6. Ventricular contractility and circulating catecholamine levels in control and OMX-CV-treated animals.** (A) Representative Pressure-Volume loops obtained from the left ventricle of a vehicle-treated animal during transient IVC occlusion. LV pressure is measured on the y-axis and LV volume on the x-axis. The superimposed line tangential to the end systolic pressure volume points of each family of loops defines the ESPVR. The family of loops in black and their corresponding ESPVR were obtained during the physiologic baseline, while the green loops and ESPVR were obtained from the same animal following 1 hour of hypoxic ventilation. (B) Representative Pressure-Volume loops obtained from the LV of an OMX-CV-treated animal during transient IVC occlusion. The family of loops in black and their corresponding ESPVR were obtained during the physiologic baseline, while the blue loops and ESPVR were obtained from the same animal following 1 hour of hypoxic ventilation. (C) Mean right ventricular contractility (as assessed by slope of the ESPVR relative to baseline) in vehicle- ( $n = 7$ ) and OMX-CV-treated ( $n = 6$ ) animals after 1 hour of hypoxic ventilation. Error bars represent the standard error of the mean; “\*” denotes a significant difference between groups with  $p < 0.05$ . (D) Mean left ventricular contractility (as assessed by slope of the ESPVR relative to baseline) in vehicle- ( $n = 7$ ) and OMX-CV-treated ( $n = 6$ ) animals after 1 hour of hypoxic ventilation. Error bars represent the standard error of the mean; “\*” denotes a significant difference between groups with  $p < 0.05$ . (E) Mean serum epinephrine levels (expressed as fold change relative to physiologic baseline) after 1 hour of hypoxic ventilation in vehicle- ( $n = 7$ ) and OMX-CV-treated ( $n = 6$ ) animals. Error bars represent the standard error of the mean; “\*” denotes a significant difference between groups with  $p < 0.05$ . (F) Mean serum

norepinephrine levels (expressed as fold change relative to physiologic baseline) at 1 hour of hypoxic ventilation in vehicle- and OMX-CV-treated animals. Error bars represent the standard error of the mean; “\*” denotes a significant difference between groups with  $p < 0.05$ . Primary data can be found in [S1 Table](#). bsln, baseline; ESPVR, end systolic pressure-volume relationship; IVC, inferior vena cava; LV, left ventricle; mmHg, millimeters mercury; OMX-CV, Omnixo-cardiovascular; RV, right ventricle; Veh, vehicle.

<https://doi.org/10.1371/journal.pbio.2005924.g006>

noted a significant increase in the levels of these catecholamines under hypoxic stress, marking an activated sympathetic response. Interestingly, we found a significant difference in the levels of epinephrine and norepinephrine between the OMX-CV- and vehicle-treated animals ( $n = 7$  control and  $n = 6$  OMX-CV), with hypoxia inducing an approximately 3-fold higher increase in both hormones in the vehicle group compared with OMX-CV ([Fig 6E and 6F](#)). Thus, increased adrenergic signaling was not responsible for the improved myocardial contractility of OMX-CV-treated animals compared with the control group, although the improved performance in the presence of the lower induction of catecholamines suggests a greater capacity of the OMX-CV-treated myocardium to respond to adrenergic signaling under hypoxic stress. We therefore conclude that while cardiac output can be maintained during severe acute alveolar hypoxia through diverse adaptive mechanisms, OMX-CV directly improves the intrinsic contractile function of the heart by virtue of its ability to increase myocardial  $O_2$  content.

## Discussion

Here, we have provided preclinical data highlighting the therapeutic efficacy of the OMX-CV biotherapeutic in relieving hypoxic myocardial dysfunction in a large animal model. H-NOX-based variants are ideally suited for  $O_2$  delivery to hypoxic tissues, such as the myocardium, because of their  $O_2$  affinity as well as pharmacokinetic and safety profiles [13]. OMX-CV's  $O_2$  affinity aligns extremely well with the unique  $O_2$  demands and microenvironments encountered within the stressed heart, its half-life enables long-term efficacy following single intravenous infusion, and its  $O_2$  specificity minimizes the vasoactive side effects encountered with HBOCs.

The cardiovascular system responds to acute hypoxia by attempting to augment and enhance systemic  $O_2$  delivery. Cardiac output increases with accompanying elevations in both HR and contractile state, which further escalate myocardial  $O_2$  demand. In response to the high and variable demand for  $O_2$  during states of acute stress, as well as the tight interrelationship between myocardial function and  $O_2$  supply, the heart has evolved robust adaptive mechanisms to augment myocardial  $O_2$  delivery and extraction [28]. For example, during exercise-induced elevations in cardiac output,  $O_2$  utilization may increase by greater than 5-fold, supported by substantial increases in coronary blood flow, capillary recruitment, and increased  $O_2$  extraction [7]. Even under unstressed conditions, the heart exhibits a high  $O_2$  extraction ratio with a correspondingly low venous saturation. When demand increases, the heart has a unique capacity to increase extraction to a greater extent than other tissues [8].

Cain and colleagues initially demonstrated that global hypoxic hypoxia and anemic hypoxia induced global anaerobic metabolism at greatly differing values of mixed venous partial pressure of oxygen ( $PO_2$ ) [9]. These differences in tissue responses to the same level of hypoxia in the blood implied that simple diffusion forces are not the limiting factor to tissue  $O_2$  extraction, and Schumacker and colleagues subsequently confirmed that a constant critical  $O_2$  extraction ratio exists in dogs [29]. Although the exact mechanisms underlying these differences are unclear, the physiologic consequence is that most tissues will start to experience  $O_2$  deficiency despite a relatively high average  $O_2$  saturation of the blood exiting their capillaries. In contrast to the other tissues and organs, the myocardium can achieve a substantially higher  $O_2$  extraction ratio, only exhibiting signs of anaerobic metabolism at a critically low coronary

venous saturation [8]. This markedly hypoxic venous and end capillary blood reflects a correspondingly hypoxic tissue bed, creating the ideal cellular microenvironment to facilitate O<sub>2</sub> dissociation and delivery by OMX-CV. Consistent with this prediction, we have shown here that in the stressed, hypoxic lamb heart, myocardial oxygenation and contractile function can be preserved with the administration of OMX-CV. This is particularly remarkable given that the total amount of OMX-CV used in our studies equates to only approximately 2% of the total O<sub>2</sub> carrying capacity of the circulating Hb. Importantly, the small amount of OMX-CV administered relative to total circulating Hb serves to limit any potential negative impact on total O<sub>2</sub> bioavailability.

Furthermore, the high O<sub>2</sub> affinity of OMX-CV precludes O<sub>2</sub> delivery under non-hypoxic conditions. This is in marked contrast to the less avid delivery profile of Hb and most HBOCs, which have been shown to contribute to pathologic hyperoxygenation of tissue and circulatory microenvironments [30]. This excessive O<sub>2</sub> release has been shown to cause oxidative stress to the tissues through the production of toxic reactive oxygen species (ROS) and to induce detrimental microvascular shunting mechanisms that may inappropriately impair tissue perfusion. Delivery of excess O<sub>2</sub> in the setting of shock is a frequent contributor to microcirculatory shunting with significant clinical consequences [31]. While vascular indices can frequently be normalized within the macrocirculation in the setting of shock, tissue perfusion can nevertheless be compromised because of shunting at the microcirculatory level. Importantly, in adult patients with severe sepsis and traumatic hemorrhagic shock, for example, the loss of coherence between the resuscitated macrocirculation and the microcirculation is one of the most sensitive and specific hemodynamic indicators associated with increased multi-organ failure and mortality [32,33,34,35]. Similarly, in critically ill children with sepsis, a persistently altered microcirculation has been associated with increased mortality [36]. OMX-CV allows a more targeted delivery of O<sub>2</sub> to only the most hypoxic tissue beds and may help alleviate the underappreciated but significant morbidities associated with excessive tissue oxygenation in this setting.

Interestingly, we noted in our study that OMX-CV administration was associated with a smaller increase in circulating catecholamine levels in the setting of systemic hypoxia. While it is unclear what exactly underlies this difference in catecholamine production and release, it does suggest potential implications related to cardiac function. Hypoxia is a well-established stimulus for catecholamine secretion both *in vitro* and *in vivo* [37,38,39], and adrenergic responses to hypoxic stress are important for the maintenance of cardiorespiratory homeostasis [40,41]. In the perinatal period, catecholamine production by adrenomedullary chromaffin cells is directly stimulated by cellular hypoxia [42,43]. However, as mammals age, this primary cellular response to O<sub>2</sub> is blunted and cholinergic innervation becomes the predominant regulatory mechanism [44]. The sympathetic response to hypoxia therefore matures to reflect the integrated input from peripheral and central chemoreceptors. In our juvenile lamb model of systemic hypoxia, OMX-CV administration appears to blunt hypoxia-driven catecholamine production. It is not clear if this reflects augmented O<sub>2</sub> delivery to chemoreceptors or the chromaffin cells themselves, or perhaps represents some secondary mechanism related to more favorable hemodynamics associated with improved myocardial oxygenation. Importantly, in the control animals, diminished cardiac contractility is observed despite dramatically elevated levels of circulating catecholamines, while the OMX-CV-treated animals exhibit preserved contractility despite smaller increases in catecholamine levels. Epinephrine and norepinephrine are potent inotropes, vital to the regulation of cardiac contractility and hemodynamic function in response to physiologic stress. Here, we show that OMX-CV supports preservation of the cardiac response to these key regulators, which are important not only as endogenous hormones but also as exogenous agents heavily utilized for cardiovascular support in critical care medicine.



With respect to its safety profile, OMX-CV exhibits significant advantages over previously developed HBOCs [45]. As the protein responsible for storage and transport of O<sub>2</sub> in red blood cells (RBCs) [46], Hb has been the precursor for the synthesis and formulation of HBOCs previously developed as RBC substitutes [47,48,49,50]. The first HBOC to be developed in this capacity consisted of partially purified “stroma-free” Hb [51]. However, transfusion of acellular Hb led to several major side effects [52,53,54,55,56]. Extracellular tetrameric Hb readily dissociates into two pairs of dimers [53,54], which are extremely prone to oxidation [56] and enhanced renal excretion [53,57]. Hb oxidation to methemoglobin (metHb) promotes unfolding of the globin chains and releases cytotoxic heme into the circulation, leading to kidney tubule damage and eventual renal failure [53,54]. Furthermore, metHb can no longer carry O<sub>2</sub> and can also contribute to the generation of harmful ROS [52,55]. Additionally, extracellular Hb can trigger vasoconstriction and systemic hypertension by various mechanisms [30,58,59]. Foremost amongst these is the indiscriminate scavenging of NO, an important intrinsic vasodilator that is locally produced by endothelial cells to relax vascular smooth muscle [58,60]. Also, potentially important is the hyperoxygenation of local vasculature that can elicit inappropriate vasoconstriction within the microcirculation, compared to more tempered O<sub>2</sub> delivery into the vessel lumen from physiologic RBC-encapsulated Hb [30,45]. Overall, the presence of extracellular Hb in the circulation may lead to direct tissue toxicity via heme release and ROS generation, while simultaneously impairing blood flow because of pathologic alterations in vasomotor tone. With its unique structure and O<sub>2</sub>-binding characteristics, OMX-CV averts the potential for many of these deleterious side effects. In this study, we have shown a lack of direct vasoreactivity in both the systemic and pulmonary vascular beds, providing strong evidence for selective O<sub>2</sub> delivery in severely hypoxic microenvironments and lack of vasoactivity.

In summary, we present preclinical data from a large animal model highlighting the therapeutic efficacy of a novel O<sub>2</sub> delivery biotherapeutic agent, OMX-CV, in relieving hypoxic myocardial dysfunction. OMX-CV is ideally suited for myocardial O<sub>2</sub> delivery because of its unique O<sub>2</sub>-binding characteristics and safety profile. Its high O<sub>2</sub> affinity complements the unique O<sub>2</sub> demands and microenvironments encountered within the stressed heart, while its low reactivity with NO minimizes the vasoactive side effects encountered with HBOCs. Additionally, while exogenous O<sub>2</sub> administration can increase systemic arterial O<sub>2</sub> content, it can also result in microvascular shunting mechanisms that limit deep tissue oxygenation [61,62]. OMX-CV therefore has the potential to improve oxygenation in a wide range of tissues and clinical scenarios in which O<sub>2</sub> delivery may be compromised.

## Materials and methods

### Ethics statement

All protocols and procedures for this work were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco. AN155428.

### Surgeries

In this study, 13 juvenile lambs (4–6 weeks of age) were anesthetized with fentanyl, ketamine, and diazepam and paralyzed with vecuronium to facilitate intubation and mechanical ventilation. Ongoing sedation and neuromuscular blockade were administered as a continuous infusion of ketamine, fentanyl, diazepam, and vecuronium. The sedative mixture was titrated to maintain age-appropriate HR. Femoral venous and arterial access were obtained via cutdown of the hind limbs, and arterial pressure was continuously transduced and recorded. The animals were ventilated with 21% FiO<sub>2</sub> initially, with a positive end expiratory pressure of 5 cm



H<sub>2</sub>O, tidal volumes of 10 mL/kg, and respiratory rate titrated to maintain pCO<sub>2</sub> of 35–45 millimeters mercury (mmHg) by arterial blood gas measurements. Thoracotomy was performed and Sorenson Neonatal Transducers (Abbott Critical Care Systems, N. Chicago, IL) were introduced into the left and right atria and main pulmonary artery (MPA) to continually transduce and record pressures. An ultrasonic flow probe (Transonics Systems, Ithaca, NY) was placed on the left pulmonary artery (LPA) to continuously monitor and record blood flow. Admittance PV catheters (Transonics Systems, Ithaca, NY) were introduced into the RV and LV via ventriculostomy to perform ventricular pressure volume analysis. These catheters consist of a solid-state sensor that directly measures pressure with high precision and excitation and recording electrodes that measure volume based on electrical admittance. Alternating current applied to the excitation electrodes generates an electrical field within the ventricle and the recording electrodes measure voltage changes, allowing calculation of resistance and conductance. With input of a measured blood resistivity and baseline stroke volume (as assessed by total cardiac output estimate from LPA flow/HR), time varying conductance can be used to solve for ventricular blood volume in real time [63]. Animals with Hb levels of less than 7.5 g/dL following surgical instrumentation were transfused with fresh whole maternal blood in increments of 5 mL/kg to achieve this minimum threshold.

Following instrumentation, the animals were allowed to recover to steady state until they required no further adjustment to sedatives and exhibited stable hemodynamic parameters. This time was designated as the normoxic baseline and blood gas analysis was performed. Baseline ventricular ESPVR was assessed by transient IVC occlusion. Following baseline assessment, the animals were subjected to sustained alveolar hypoxia by ventilation with an admixture of atmospheric gas and nitrogen to achieve a FiO<sub>2</sub> of 10%. Arterial blood gas analysis was performed every 15 minutes with blood withdrawn from the femoral artery and analyzed using a Radiometer ABL5 pH/blood gas analyzer (Radiometer, Copenhagen, Denmark). Ventilatory rate was adjusted to maintain PCO<sub>2</sub> 35–45 mmHg and metabolic acidosis was corrected with NaHCO<sub>3</sub> boluses to maintain pH >7.30.

### Animal care and use

All protocols and procedures for this work were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco. Animals' vital signs, including core temperature, were monitored throughout the study, and they were given intravenous fluids and prophylactic antibiotics per protocol. At the end of each protocol, all lambs were euthanized with a lethal injection of sodium pentobarbital followed by bilateral thoracotomy, as described in the NIH Guidelines for the Care and Use of Laboratory Animals.

### OMX-CV production

The engineered Tt H-NOX protein described in this study was produced by QuikChange Site-Directed Mutagenesis (Agilent), subcloned into an expression plasmid, transformed into *Escherichia coli*, and expressed essentially as described [11]. Cells were harvested by hollow-fiber tangential-flow filtration and processed immediately. The His-tagged Tt H-NOX protein was purified from cell lysate using Ni-affinity chromatography and further polished by passage over an anion-exchange column to remove remaining host cell DNA, host cell proteins, and endotoxins. The purified protein was formulated to produce OMX-CV, and frozen at –80 °C until use. Protein concentrations were determined using UV-Vis spectrophotometry as described [11]. Prior to use in animal studies, OMX-CV was subjected to purity testing by SDS-PAGE (Invitrogen) and SEC-HPLC (Agilent) and safety testing by kinetic chromogenic

LAL test for endotoxin (Charles River Laboratories). For use in animal studies, proteins lots were required to be greater than 95% pure and have endotoxin levels less than 0.1 EU/mg.

### OMX-CV administration

After 15 minutes of alveolar hypoxia, the animals received either 200 mg/kg of OMX-CV (about 4 mL/kg by volume) as a bolus over 10 minutes, followed by continuous infusion at 70 mg/kg/hour (OMX-CV group  $n = 6$ ), or an equivalent volume of the OMX-CV vehicle solution administered in the same manner (control group  $n = 7$ ). At 60 minutes of alveolar hypoxia, repeat evaluation of the ESPVR was assessed by IVC occlusion.

### Physiologic monitoring

Physiologic data were continuously recorded and analyzed using the Ponemah Physiology Platform (Data Sciences International, New Brighton, MN) with Acquisition Interface, ACQ-7700 (Data Sciences International, St. Paul, MN). For calculation of total cardiac output, LPA blood flow was assumed to represent 45% of total output, as previously established in juvenile lambs by Rudolph. This was indexed to animal size by dividing by the animal's body weight in kilograms. PVR was calculated as the difference of mean pulmonary arterial pressure and left atrial pressure divided by the indexed cardiac output. SVR was calculated as the difference of mean systemic arterial pressure and right atrial pressure divided by the indexed cardiac output. Pressure volume loop recording and analysis were performed using Labscribe software (iWorx, Dover, NH).

### Epinephrine and norepinephrine ELISA

At baseline and again at 60 minutes of hypoxia, plasma and serum samples were collected from all animals ( $n = 7$  control and  $n = 6$  OMX-CV) for additional analysis, including measurement of circulating catecholamines. Determination of epinephrine and norepinephrine levels in plasma was performed using a colorimetric ELISA kit (ABNOVA) according to the manufacturer's instructions.

### Pimonidazole ELISA

In a subset of animals ( $n = 3$  control and  $n = 3$  OMX-CV), following the final physiologic assessment, pimonidazole (85 mg/kg) was administered intravenously over 10–15 minutes, as tolerated. Thirty minutes following the pimonidazole infusion, the animals were euthanized for tissue collection. Myocardial tissues were snap-frozen and proteins were then extracted and processed for competitive pimonidazole ELISA, as described [64]. Standard curves for the pimonidazole ELISA were fit using a five-parameter logistic equation and used to determine  $IC_{50}$  values. Values were normalized to the protein concentration in each sample and then expressed relative to the vehicle control.

### Immunohistochemistry of pimonidazole and OMX-CV

Myocardial tissues were frozen in OCT and processed for cryosectioning, followed by immunohistochemical analysis. Sections were fixed with 100% methanol for 20 minutes at  $-20^{\circ}\text{C}$ , then blocked and permeabilized with 5% BSA, 5% goat serum, and 0.1% Tween 20 for 1–2 hours at room temperature. Sections were then incubated with anti-pimonidazole (Hypoxyprobe, 1:100), anti-OMX-CV (1:200, Mouse monoclonal) antibodies overnight at  $4^{\circ}\text{C}$ , followed by anti-rabbit or anti-mouse secondary antibodies (1:1,000, Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 hours at room temperature. The sections were mounted in

SlowFade DAPI (Invitrogen) and imaged at the UCSF Laboratory for Cell Analysis Core with an HD AxioImager Zeiss microscope equipped with a CCD digital camera.

### Statistical analysis

Comparison of physiologic data comparing pre-hypoxic baseline to the first hypoxic physiologic time point was performed using a paired Student *t* test. Evaluation of cardiac output over the duration of the study between groups was performed using two-way ANOVA analysis. Evaluation of PVR and SVR before and after treatment between groups was performed using two-way ANOVA analysis. Pimnidazole levels were compared between groups using an unpaired Student *t* test. For ESPVR data, the slope of the ESPVR at 60 minutes of hypoxia for each ventricle of each animal was normalized to its own baseline ESPVR. These normalized values were then compared between groups using an unpaired Student *t* test. Epinephrine and norepinephrine levels at 60 minutes of hypoxia were compared between groups using unpaired Student *t* test. For all statistical tests performed,  $p \leq 0.05$  was considered to be significant. All analyses were performed using GraphPad Prism version 6.04 for Macintosh, GraphPad Software, La Jolla, CA.

### Supporting information

**S1 Table. Individual numerical values that underlie all numerical data, represented in either graphical or table form and arranged as individual worksheets by figure or table number.**

(XLSX)

### Author Contributions

**Conceptualization:** Jonathan A. Winger, Stephen P. Cary, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Data curation:** Jason Boehme, Natacha Le Moan, Rebecca J. Kameny, Brian D. Goudy, Janel Long-Boyle, Vijay Ivaturi, Jogarao V. S. Gobburu, Jonathan A. Winger, Sanjeev A. Datar, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Formal analysis:** Jason Boehme, Natacha Le Moan, Rebecca J. Kameny, Janel Long-Boyle, Vijay Ivaturi, Sanjeev A. Datar, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Funding acquisition:** Stephen P. Cary, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Investigation:** Jason Boehme, Rebecca J. Kameny, Alexandra Loucks, Michael J. Johengen, Amy L. Lesneski, Wenhui Gong, Brian D. Goudy, Tina Davis, Andrew Davis, Youping He, Vijay Ivaturi, Jogarao V. S. Gobburu, Sanjeev A. Datar, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Methodology:** Jason Boehme, Rebecca J. Kameny, Alexandra Loucks, Michael J. Johengen, Amy L. Lesneski, Wenhui Gong, Brian D. Goudy, Tina Davis, Kevin Tanaka, Andrew Davis, Youping He, Janel Long-Boyle, Vijay Ivaturi, Jonathan A. Winger, Sanjeev A. Datar, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Project administration:** Natacha Le Moan, Rebecca J. Kameny, Alexandra Loucks, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Resources:** Natacha Le Moan, Rebecca J. Kameny, Alexandra Loucks, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Supervision:** Natacha Le Moan, Rebecca J. Kameny, Michael J. Johengen, Kevin Tanaka, Youping He, Janel Long-Boyle, Vijay Ivaturi, Jogarao V. S. Gobburu, Jonathan A. Winger, Stephen P. Cary, Sanjeev A. Datar, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

**Validation:** Jason Boehme, Natacha Le Moan, Rebecca J. Kameny, Brian D. Goudy, Janel Long-Boyle, Sanjeev A. Datar, Emin Maltepe.

**Visualization:** Jason Boehme, Natacha Le Moan, Rebecca J. Kameny, Alexandra Loucks, Ana Krtolica, Emin Maltepe.

**Writing – original draft:** Jason Boehme, Jeffrey R. Fineman, Emin Maltepe.

**Writing – review & editing:** Jason Boehme, Natacha Le Moan, Alexandra Loucks, Janel Long-Boyle, Jonathan A. Winger, Stephen P. Cary, Sanjeev A. Datar, Jeffrey R. Fineman, Ana Krtolica, Emin Maltepe.

## References

1. Kutko MC, Calarco MP, Flaherty MB, Helmrich RF, Ushay HM, et al. (2003) Mortality rates in pediatric septic shock with and without multiple organ system failure. *Pediatr Crit Care Med* 4: 333–337. <https://doi.org/10.1097/01.PCC.0000074266.10576.9B> PMID: 12831416
2. Martin GS (2012) Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. *Expert Rev Anti Infect Ther* 10: 701–706. <https://doi.org/10.1586/eri.12.50> PMID: 22734959
3. Heckbert SR, Vedder NB, Hoffman W, Winn RK, Hudson LD, et al. (1998) Outcome after hemorrhagic shock in trauma patients. *J Trauma* 45: 545–549. PMID: 9751548
4. Reynolds HR, Hochman JS (2008) Cardiogenic shock: current concepts and improving outcomes. *Circulation* 117: 686–697. <https://doi.org/10.1161/CIRCULATIONAHA.106.613596> PMID: 18250279
5. Taegtmeyer H (1994) Energy metabolism of the heart: from basic concepts to clinical applications. *Curr Probl Cardiol* 19: 59–113. PMID: 8174388
6. Neely JR, Rovetto MJ, Oram JF (1972) Myocardial utilization of carbohydrate and lipids. *Prog Cardiovasc Dis* 15: 289–329. PMID: 4564017
7. von Restorff W, Holtz J, Bassenge E (1977) Exercise induced augmentation of myocardial oxygen extraction in spite of normal coronary dilatatory capacity in dogs. *Pflugers Arch* 372: 181–185. PMID: 564040
8. Walley KR, Collins RM, Cooper DJ, Warriner CB (1997) Myocardial anaerobic metabolism occurs at a critical coronary venous PO<sub>2</sub> in pigs. *Am J Respir Crit Care Med* 155: 222–228. <https://doi.org/10.1164/ajrccm.155.1.9001316> PMID: 9001316
9. Cain SM (1977) Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. *J Appl Physiol Respir Environ Exerc Physiol* 42: 228–234. <https://doi.org/10.1152/jappl.1977.42.2.228> PMID: 14097
10. Walley KR, Becker CJ, Hogan RA, Teplinsky K, Wood LD (1988) Progressive hypoxemia limits left ventricular oxygen consumption and contractility. *Circ Res* 63: 849–859. PMID: 3180352
11. Karow DS, Pan D, Tran R, Pellicena P, Presley A, et al. (2004) Spectroscopic characterization of the soluble guanylate cyclase-like heme domains from *Vibrio cholerae* and *Thermoanaerobacter tengcongensis*. *Biochemistry* 43: 10203–10211. <https://doi.org/10.1021/bi049374l> PMID: 15287748
12. Boon EM, Marletta MA (2005) Ligand discrimination in soluble guanylate cyclase and the H-NOX family of heme sensor proteins. *Curr Opin Chem Biol* 9: 441–446. <https://doi.org/10.1016/j.cbpa.2005.08.015> PMID: 16125437
13. LeMoan N, Leung PY, Rost N, Winger JA, A. AK, et al. (2017) A New Paradigm in Protecting Ischemic Brain: Preserving the Neurovascular Unit Before Reperfusion; Lapchak P. Z J, editor: Springer, Cham.
14. Chen JY, Scerbo M, Kramer G (2009) A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. *Clinics (Sao Paulo)* 64: 803–813.
15. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM (2008) Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. *JAMA* 299: 2304–2312. <https://doi.org/10.1001/jama.299.19.jrv80007> PMID: 18443023
16. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, et al. (2004) No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. *Free Radic Biol Med* 36: 685–697. <https://doi.org/10.1016/j.freeradbiomed.2003.11.030> PMID: 14990349

17. The PyMOL Molecular Graphics System, Version 1.5 Schrödinger, LLC.
18. Helmerhorst HJ, Schultz MJ, van der Voort PH, de Jonge E, van Westerloo DJ (2015) Bench-to-bedside review: the effects of hyperoxia during critical illness. *Crit Care* 19: 284. <https://doi.org/10.1186/s13054-015-0996-4> PMID: 26278383
19. Rudolph AM (2009) *Congenital diseases of the heart: clinical-physiological considerations*. Chichester, UK; Hoboken, NJ: Wiley-Blackwell. 538 p. p.
20. Kontos HA, Mauck HP Jr., Richardson DW, Patterson JL Jr. (1965) Mechanism of Circulatory Responses to Systemic Hypoxia in the Anesthetized Dog. *Am J Physiol* 209: 397–403. <https://doi.org/10.1152/ajplegacy.1965.209.2.397> PMID: 14321140
21. Downing SE, Gardner TH, Rocamora JM (1969) Adrenergic support of cardiac function during hypoxia in the newborn lamb. *Am J Physiol* 217: 728–735. <https://doi.org/10.1152/ajplegacy.1969.217.3.728> PMID: 5807695
22. Moudgil R, Michelakis ED, Archer SL (2005) Hypoxic pulmonary vasoconstriction. *J Appl Physiol* (1985) 98: 390–403.
23. Aaronson PI, Robertson TP, Ward JP (2002) Endothelium-derived mediators and hypoxic pulmonary vasoconstriction. *Respir Physiol Neurobiol* 132: 107–120. PMID: 12126699
24. Blitzer ML, Loh E, Roddy MA, Stamler JS, Creager MA (1996) Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. *J Am Coll Cardiol* 28: 591–596. PMID: 8772744
25. Arteel GE, Thurman RG, Raleigh JA (1998) Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. *Eur J Biochem* 253: 743–750. PMID: 9654074
26. Suga H, Sagawa K, Shoukas AA (1973) Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. *Circ Res* 32: 314–322. PMID: 4691336
27. Baan J, van der Velde ET, Steendijk P (1992) Ventricular pressure-volume relations in vivo. *Eur Heart J* 13 Suppl E: 2–6.
28. Duncker DJ, Koller A, Merkus D, Cauty JM Jr. (2015) Regulation of coronary blood flow in health and ischemic heart disease. *Prog Cardiovasc Dis* 57: 409–422. <https://doi.org/10.1016/j.pcad.2014.12.002> PMID: 25475073
29. Schumacker PT, Long GR, Wood LD (1987) Tissue oxygen extraction during hypovolemia: role of hemoglobin P50. *J Appl Physiol* (1985) 62: 1801–1807.
30. Winslow RM (2008) Cell-free oxygen carriers: scientific foundations, clinical development, and new directions. *Biochim Biophys Acta* 1784(10):1382–6. <https://doi.org/10.1016/j.bbapap.2008.04.032> PMID: 18555029
31. Kuiper JW, Tibboel D, Ince C (2016) The vulnerable microcirculation in the critically ill pediatric patient. *Crit Care* 20: 352. <https://doi.org/10.1186/s13054-016-1496-x> PMID: 27794361
32. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL (2004) Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. *Crit Care Med* 32: 1825–1831. PMID: 15343008
33. De Backer D, Creteur J, Dubois MJ, Sakr Y, Vincent JL (2004) Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. *Am Heart J* 147: 91–99. PMID: 14691425
34. De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, et al. (2013) Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. *Crit Care Med* 41: 791–799. <https://doi.org/10.1097/CCM.0b013e3182742e8b> PMID: 23318492
35. Tachon G, Harrois A, Tanaka S, Kato H, Huet O, et al. (2014) Microcirculatory alterations in traumatic hemorrhagic shock. *Crit Care Med* 42: 1433–1441. <https://doi.org/10.1097/CCM.0000000000000223> PMID: 24561562
36. Top AP, Ince C, de Meij N, van Dijk M, Tibboel D (2011) Persistent low microcirculatory vessel density in nonsurvivors of sepsis in pediatric intensive care. *Crit Care Med* 39: 8–13. <https://doi.org/10.1097/CCM.0b013e3181fb7994> PMID: 21076287
37. Cheung CY (1989) Direct adrenal medullary catecholamine response to hypoxia in fetal sheep. *J Neurochem* 52: 148–153. PMID: 2908885
38. Donnelly DF, Doyle TP (1994) Developmental changes in hypoxia-induced catecholamine release from rat carotid body, in vitro. *J Physiol* 475: 267–275. PMID: 8021833
39. Kumar GK, Overholt JL, Bright GR, Hui KY, Lu H, et al. (1998) Release of dopamine and norepinephrine by hypoxia from PC-12 cells. *Am J Physiol* 274: C1592–1600. PMID: 9611124



40. Gamboa A, Gamboa JL, Holmes C, Sharabi Y, Leon-Velarde F, et al. (2006) Plasma catecholamines and blood volume in native Andeans during hypoxia and normoxia. *Clin Auton Res* 16: 40–45. <https://doi.org/10.1007/s10286-006-0305-z> PMID: 16477494
41. Kanstrup IL, Poulsen TD, Hansen JM, Andersen LJ, Bestle MH, et al. (1999) Blood pressure and plasma catecholamines in acute and prolonged hypoxia: effects of local hypothermia. *J Appl Physiol* (1985) 87: 2053–2058.
42. Salman S, Buttigieg J, Nurse CA (2014) Ontogeny of O<sub>2</sub> and CO<sub>2</sub>/H<sup>+</sup> chemosensitivity in adrenal chromaffin cells: role of innervation. *J Exp Biol* 217: 673–681. <https://doi.org/10.1242/jeb.086165> PMID: 24574383
43. Richter S, Qin N, Pacak K, Eisenhofer G (2013) Role of hypoxia and HIF2alpha in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. *Adv Pharmacol* 68: 285–317. <https://doi.org/10.1016/B978-0-12-411512-5.00014-2> PMID: 24054150
44. Kumar GK, Peng YJ, Nanduri J, Prabhakar NR (2015) Carotid Body Chemoreflex Mediates Intermittent Hypoxia-Induced Oxidative Stress in the Adrenal Medulla. *Adv Exp Med Biol* 860: 195–199. [https://doi.org/10.1007/978-3-319-18440-1\\_21](https://doi.org/10.1007/978-3-319-18440-1_21) PMID: 26303481
45. Cabrales P, Intaglietta M (2013) Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids. *ASAIO J* 59: 337–354. <https://doi.org/10.1097/MAT.0b013e318291fbaa> PMID: 23820271
46. Lehninger AL, Nelson DL, Cox MM (2013) *Lehninger principles of biochemistry*. New York: W.H. Freeman.
47. Gould SA, Moore EE, Hoyt DB, Burch JM, Haenel JB, et al. (1998) The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. *J Am Coll Surg* 187: 113–120; discussion 120–112. PMID: 9704955
48. Moore EE, Moore FA, Fabian TC, Bernard AC, Fulda GJ, et al. (2009) Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. *J Am Coll Surg* 208: 1–13. <https://doi.org/10.1016/j.jamcollsurg.2008.09.023> PMID: 19228496
49. Greenburg AG, Kim HW, Hemolink Study G (2004) Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. *J Am Coll Surg* 198: 373–383; discussion 384–375. <https://doi.org/10.1016/j.jamcollsurg.2003.11.020> PMID: 14992738
50. Jahr JS, Moallempour M, Lim JC (2008) HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation). *Expert Opin Biol Ther* 8: 1425–1433.
51. Gilligan DR, Altschule MD, Katersky EM (1941) Studies of Hemoglobinemia and Hemoglobinuria Produced in Man by Intravenous Injection of Hemoglobin Solutions. *J Clin Invest* 20: 177–187. <https://doi.org/10.1172/JCI101210> PMID: 16694823
52. Bulow L, Alayash AI (2017) Redox Chemistry of Hemoglobin-Associated Disorders. *Antioxid Redox Signal*.
53. Bunn HF, Esham WT, Bull RW (1969) The renal handling of hemoglobin. I. Glomerular filtration. *J Exp Med* 129: 909–923. PMID: 5778789
54. Chan WL, Tang NL, Yim CC, Lai FM, Tam MS (2000) New features of renal lesion induced by stroma free hemoglobin. *Toxicol Pathol* 28: 635–642. <https://doi.org/10.1177/019262330002800501> PMID: 11026597
55. Dunne J, Caron A, Menu P, Alayash AI, Buehler PW, et al. (2006) Ascorbate removes key precursors to oxidative damage by cell-free haemoglobin in vitro and in vivo. *Biochem J* 399: 513–524. <https://doi.org/10.1042/BJ20060341> PMID: 16848758
56. Zhang L, Levy A, Rifkind JM (1991) Autooxidation of hemoglobin enhanced by dissociation into dimers. *J Biol Chem* 266: 24698–24701. PMID: 1761565
57. Bunn HF, Jandl JH (1969) The renal handling of hemoglobin. II. Catabolism. *J Exp Med* 129: 925–934. PMID: 5778790
58. Kavdia M, Tsoukias NM, Popel AS (2002) Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. *Am J Physiol Heart Circ Physiol* 282: H2245–2253. <https://doi.org/10.1152/ajpheart.00972.2001> PMID: 12003834
59. Gibson QH, Roughton FJ (1965) Further studies on the kinetics and equilibria of the reaction of nitric oxide with haemoproteins. *Proc R Soc Lond B Biol Sci* 163: 197–205. PMID: 4378479
60. Gibson QH, Roughton FJ (1957) The kinetics and equilibria of the reactions of nitric oxide with sheep haemoglobin. *J Physiol* 136: 507–524. PMID: 13429517
61. Ince C, Mik EG (2016) Microcirculatory and mitochondrial hypoxia in sepsis, shock, and resuscitation. *J Appl Physiol* (1985) 120: 226–235.



62. Kanoore Edul VS, Ince C, Dubin A (2015) What is microcirculatory shock? *Curr Opin Crit Care* 21: 245–252. <https://doi.org/10.1097/MCC.0000000000000196> PMID: 25827583
63. Porterfield JE, Kottam ATG, Raghavan K, Escobedo D, Jenkins JT, et al. (2009) Dynamic correction for parallel conductance, GP, and gain factor,  $\alpha$ , in invasive murine left ventricular volume measurements. *J Appl Physiol* 107: 1693–1703. <https://doi.org/10.1152/jappphysiol.91322.2008> PMID: 19696357
64. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DY, et al. (2006) A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. *Int J Radiat Oncol Biol Phys* 64: 592–602. <https://doi.org/10.1016/j.ijrobp.2005.09.010> PMID: 16289910